Review article: COVID-19 and liver disease-what we know on 1st May 2020.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
15
04
2020
revised:
01
05
2020
accepted:
04
05
2020
pubmed:
14
5
2020
medline:
14
7
2020
entrez:
14
5
2020
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19), became a global threat to human health. Liver impairment has been frequently reported as a common manifestation, although its clinical significance is still unclear, particularly in patients with underlying chronic liver disease (CLD). To summarise the changes in liver function tests during SARS-CoV-2 infection and the impact of COVID-19 in patients with underlying CLD. A literature review using online database PubMed was done using the search terms "SARS-CoV-2", "COVID-19", "liver", "cirrhosis" and "liver transplantation". COVID-19 is frequently associated with different degrees of abnormal liver function tests, most notably transaminases, which are usually transitory and of mild degree. Available evidence suggests that liver injury may result from direct pathogenic effect by the virus, systemic inflammation or toxicity from commonly used drugs in this subset of patients. SARS-CoV-2 infection in children is associated with minimal or no increase in liver enzymes, thus the presence of abnormal liver function tests should trigger evaluation for underlying liver diseases. Although it seems that patients with CLD are not at greater risk for acquiring the infection, those with cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease, autoimmune liver diseases or liver transplant may have a greater risk for severe COVID-19. Abnormal liver function tests during the course of COVID-19 are common, though clinically significant liver injury is rare. Further research is needed focusing on the effect of existing liver-related comorbidities on treatment and outcome of COVID-19.
Sections du résumé
BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19), became a global threat to human health. Liver impairment has been frequently reported as a common manifestation, although its clinical significance is still unclear, particularly in patients with underlying chronic liver disease (CLD).
AIMS
To summarise the changes in liver function tests during SARS-CoV-2 infection and the impact of COVID-19 in patients with underlying CLD.
METHODS
A literature review using online database PubMed was done using the search terms "SARS-CoV-2", "COVID-19", "liver", "cirrhosis" and "liver transplantation".
RESULTS
COVID-19 is frequently associated with different degrees of abnormal liver function tests, most notably transaminases, which are usually transitory and of mild degree. Available evidence suggests that liver injury may result from direct pathogenic effect by the virus, systemic inflammation or toxicity from commonly used drugs in this subset of patients. SARS-CoV-2 infection in children is associated with minimal or no increase in liver enzymes, thus the presence of abnormal liver function tests should trigger evaluation for underlying liver diseases. Although it seems that patients with CLD are not at greater risk for acquiring the infection, those with cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease, autoimmune liver diseases or liver transplant may have a greater risk for severe COVID-19.
CONCLUSIONS
Abnormal liver function tests during the course of COVID-19 are common, though clinically significant liver injury is rare. Further research is needed focusing on the effect of existing liver-related comorbidities on treatment and outcome of COVID-19.
Identifiants
pubmed: 32402090
doi: 10.1111/apt.15813
pmc: PMC7272838
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
267-275Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Int J Infect Dis. 2020 May;94:81-87
pubmed: 32205284
Allergy. 2020 Jul;75(7):1742-1752
pubmed: 32239761
Gut. 2020 Jun;69(6):1002-1009
pubmed: 32213556
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
Pharmacotherapy. 2020 May;40(5):416-437
pubmed: 32259313
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Zhonghua Er Ke Za Zhi. 2020 Apr 2;58(4):269-274
pubmed: 32118389
Arthritis Rheumatol. 2017 Sep;69(9):1751-1761
pubmed: 28597609
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Am J Transplant. 2020 Jul;20(7):1907-1910
pubmed: 32277591
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
J Clin Pharmacol. 2002 Oct;42(10):1122-33
pubmed: 12362927
Hepatol Int. 2020 Jul;14(4):432-436
pubmed: 32277387
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
PLoS One. 2020 Jul 9;15(7):e0235458
pubmed: 32645044
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
Liver Int. 2020 Sep;40(9):2095-2103
pubmed: 32239796
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):529-530
pubmed: 32203680
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Liver Int. 2020 May;40(5):998-1004
pubmed: 32170806
Arch Toxicol. 2020 Apr;94(4):1367-1369
pubmed: 32266419
FASEB J. 2020 May;34(5):6027-6037
pubmed: 32350928
HIV Clin Trials. 2011 Sep-Oct;12(5):235-43
pubmed: 22180521
Lancet. 2020 Feb 8;395(10222):391-393
pubmed: 32035533
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S90-7
pubmed: 14986280
Hepatology. 2020 Oct;72(4):1491-1493
pubmed: 32220017
BMJ. 2020 Feb 19;368:m606
pubmed: 32075786
Gastroenterology. 2015 Jan;148(1):215-9; quiz e16-7
pubmed: 25447850
J Hepatol. 2019 Apr;70(4):797-799
pubmed: 30635243
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
Hepatology. 2004 Feb;39(2):302-10
pubmed: 14767982
J Virol. 2004 Dec;78(24):14043-7
pubmed: 15564512
Rheumatology (Oxford). 2012 Aug;51(8):1520-1
pubmed: 22467085
Lancet Infect Dis. 2018 Aug;18(8):e217-e227
pubmed: 29680581
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Chin Med J (Engl). 2020 May 5;133(9):1032-1038
pubmed: 32118640
Lancet Infect Dis. 2020 Jun;20(6):689-696
pubmed: 32220650
JAMA. 2020 Mar 17;323(11):1039-1040
pubmed: 32022836
J Intern Med. 2020 Jul;288(1):128-138
pubmed: 32220033
J Hepatol. 2014 Dec;61(6):1385-96
pubmed: 25135860
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
J Hepatol. 2020 Aug;73(2):453-455
pubmed: 32283134
Arthritis Rheum. 1990 Nov;33(11):1611-9
pubmed: 2242059
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
JHEP Rep. 2020 Jun;2(3):100113
pubmed: 32289115
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Am J Transplant. 2020 Jul;20(7):1891-1895
pubmed: 32243673
Int J Rheum Dis. 2017 Jul;20(7):859-869
pubmed: 28160426
Curr Opin Infect Dis. 2012 Aug;25(4):423-30
pubmed: 22766648
Clin Gastroenterol Hepatol. 2020 Jun;18(7):1561-1566
pubmed: 32283325
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):532-533
pubmed: 32278366
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
Hepatol Int. 2020 Jul;14(4):454-455
pubmed: 32277386
Transl Pediatr. 2020 Feb;9(1):51-60
pubmed: 32154135
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):528-529
pubmed: 32197093
Liver Int. 2020 Jun;40(6):1321-1326
pubmed: 32239591
J Clin Transl Hepatol. 2020 Mar 28;8(1):18-24
pubmed: 32274342
Am J Pathol. 2006 Apr;168(4):1057-9
pubmed: 16565481
World J Pediatr. 2020 Jun;16(3):222
pubmed: 32037473
Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):55-66
pubmed: 27924081
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Zhonghua Gan Zang Bing Za Zhi. 2003 Aug;11(8):493-6
pubmed: 12939186
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379
pubmed: 32242738
J Med Virol. 2020 Jul;92(7):797-806
pubmed: 32198776
Aliment Pharmacol Ther. 2020 Jul;52(2):267-275
pubmed: 32402090